Skip to content

Alpha Cognition ACOG Acquired in-process research and development

Acquired in-process research and development at other companies

Biogen logo
BiogenBIIB
$35M

Other financials

Income statement

See full
Revenue$3.5M+20.7%
Gross profit$3.3M+12.7%
Operating income-$8.1M-138%
Net income-$6.5M-276%
EPS (diluted)-$0.32-191%

Balance sheet

See full
Cash & equivalents$54.3M+100,638%
Total equity$57.5M+49.2%
Total assets$69.2M+42.5%

Cash flow

See full
Operating cash flow-$11.8M-477%
CapEx$1.3K-97.9%
Free cash flow-$11.8M-460%

Valuation

See full
Market cap$157.21M+6.6%
P/S14.5×

Profitability

See full
Gross margin89.3%
Operating margin-250.1%
Net margin-232.2%
FCF margin-280.5%

Returns & leverage

See full
Return on equity-52.4%-5.3pp
Current ratio12.6×-4.5×

Where this comes from

Reported directly by Alpha Cognition in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Alpha Cognition’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alpha Cognition's acquired in-process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alpha Cognition's acquired in-process research and development?
Alpha Cognition (ACOG) reported acquired in-process research and development of $1.1M in Q1 2026.
How has Alpha Cognition's acquired in-process research and development changed year-over-year?
Alpha Cognition's acquired in-process research and development increased by 173.8% year-over-year, from $400.42K to $1.1M.
What is the long-term trend for Alpha Cognition's acquired in-process research and development?
Over 2 years (2023 to 2025), Alpha Cognition's acquired in-process research and development has grown at a -38.2% compound annual growth rate (CAGR), from $4.88M to $1.87M.
What does acquired in-process research and development mean?
Cash expenditures related to the acquisition of research and development projects that have not yet reached technological feasibility. This is a critical indicator of a company's strategy to bolster its pipeline through external innovation rather than internal development.